Bulk Pharmaceutical API Sources for SANCUSO

Bulk Pharmaceutical API Sources for SANCUSO

Vendor	Vendor Homepage	Vendor Sku	API Url
AstaTech, Inc.		45100
AKos Consulting & Solutions		AKOS025402424
Clearsynth		CS-O-30593
Hangzhou APIChem Technology		AC-8910

Bulk Active Pharmaceutical Ingredient (API) Sources for SANCUSO

Last updated: February 19, 2026

SANCUSO (granisetron hydrochloride) is a selective serotonin 5-HT3 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV) and radiotherapy-induced nausea and vomiting (RINV). This analysis identifies and profiles key bulk Active Pharmaceutical Ingredient (API) manufacturers supplying granisetron hydrochloride. Sourcing strategies for SANCUSO API involve assessing manufacturer scale, quality certifications, regulatory compliance, and supply chain reliability.

What are the Primary Manufacturers of Granisetron Hydrochloride API?

The market for granisetron hydrochloride API is served by a consolidated group of manufacturers, primarily located in Asia, with a strong presence in India and China. These companies specialize in complex API synthesis and adhere to stringent pharmaceutical manufacturing standards.

• Granules India Ltd. is a significant producer of granisetron hydrochloride API. The company operates multiple manufacturing facilities approved by regulatory bodies including the US FDA, EDQM, and others. Their production capacity and established quality management systems position them as a key supplier for both generic and innovator pharmaceutical companies. Granules India reports substantial capacity for various APIs, including those in the oncology supportive care segment. [1]

• Divi's Laboratories Ltd. is another major API manufacturer with granisetron hydrochloride in its product portfolio. Divi's is recognized for its large-scale production capabilities and strong regulatory track record, holding approvals from US FDA, EDQM, and PMDA. Their expertise in complex chemical synthesis and process optimization contributes to their competitive position in the API market. [2]

• Laurus Labs Ltd. is an emerging player with an increasing focus on niche and complex APIs. While specific public data on their granisetron hydrochloride production volume is less detailed than larger players, Laurus Labs has demonstrated significant growth in its API segment, driven by its R&D capabilities and cGMP compliant manufacturing. [3]

• API manufacturers based in China collectively represent a substantial portion of global API supply. Companies such as WuXi AppTec and PharmaBlock offer custom synthesis and API manufacturing services, including granisetron hydrochloride. These entities often operate under strict quality control protocols and are capable of supplying large volumes to meet global demand. Specific production figures for individual Chinese API suppliers are often proprietary.

What are the Key Quality and Regulatory Standards for Granisetron Hydrochloride API?

The production of granisetron hydrochloride API must comply with rigorous international quality and regulatory standards to ensure patient safety and therapeutic efficacy. These standards are overseen by major health authorities.

• Current Good Manufacturing Practices (cGMP): All API manufacturers must adhere to cGMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceutical Affairs Bureau of Japan (PAB) (now PMDA). These regulations cover all aspects of production, from raw material sourcing to finished product release, including facility design, equipment calibration, process validation, and personnel training. [4]

• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. A DMF provides detailed information about the chemistry, manufacturing, and controls (CMC) of the API. This confidential document allows regulatory authorities to review the API’s manufacturing process without the manufacturer disclosing proprietary information to the drug product applicant. US FDA and Health Canada accept DMFs, while European authorities utilize the Active Substance Master File (ASMF) procedure, which is functionally equivalent. [5]

• Pharmacopoeial Standards: Granisetron hydrochloride API must meet the specifications outlined in major pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These monographs define the identity, purity, strength, and quality of the API, specifying tests for assay, related substances, residual solvents, and heavy metals. [6]

• International Council for Harmonisation (ICH) Guidelines: Manufacturers are expected to follow ICH guidelines, particularly those related to quality (e.g., ICH Q7 for APIs, ICH Q11 for development and manufacture of drug substances). These guidelines promote global harmonization of technical requirements for drug registration. [7]

What are the Production Capacities and Scale of Operation for Key Suppliers?

The scale of API production is a critical factor for pharmaceutical companies seeking reliable and cost-effective supply chains. Leading manufacturers have invested in significant infrastructure to meet global demand.

• Granules India Ltd. has a demonstrated track record of large-scale API production. Their facilities are designed for multi-tonnage output, supported by backward integration into key starting materials. While specific granisetron hydrochloride capacity is not publicly disclosed, the company's overall API production volume is substantial, enabling them to support high-volume drug product manufacturing. [1]

• Divi's Laboratories Ltd. is known for its world-class manufacturing facilities capable of producing APIs in hundreds of metric tons annually. Their strategic focus on process efficiency and large-scale operations allows for competitive pricing and consistent supply of critical APIs like granisetron hydrochloride. [2]

• Laurus Labs Ltd. has been rapidly expanding its manufacturing footprint. Their facilities are designed for high-volume production with advanced technology. The company has a stated strategy to increase its API manufacturing capacity across its product segments, indicating a potential for significant granisetron hydrochloride output. [3]

• Chinese API Manufacturers generally possess substantial production capacities. Many operate large, multi-purpose chemical synthesis plants that can be reconfigured to produce various APIs, including granisetron hydrochloride, in significant volumes. The competitive pricing often associated with Chinese API manufacturers stems from economies of scale and lower manufacturing costs.

What are the Supply Chain Risks and Mitigation Strategies?

Sourcing API for SANCUSO involves managing potential supply chain disruptions. Pharmaceutical companies must assess and mitigate risks related to manufacturing, regulatory compliance, geopolitical factors, and logistics.

• Manufacturing Disruptions: Incidents such as natural disasters, equipment failures, or labor disputes at a primary manufacturing site can halt production.

  • Mitigation: Dual sourcing from different geographical regions and manufacturers with robust business continuity plans. Maintaining strategic inventory levels.

• Regulatory Non-Compliance: Changes in regulatory requirements or adverse findings during inspections can lead to import alerts or production halts.

  • Mitigation: Thorough due diligence on supplier regulatory compliance history. Regular audits of manufacturing facilities and quality systems. Ensuring suppliers have up-to-date DMFs and regulatory approvals.

• Geopolitical Instability: Trade wars, political unrest, or changes in export policies in major API manufacturing countries can impact supply.

  • Mitigation: Diversifying sourcing to include manufacturers in politically stable regions. Monitoring geopolitical developments that could affect trade routes or supply agreements.

• Quality Issues: Batch failures, unexpected impurity profiles, or degradation can lead to product recalls and supply shortages.

  • Mitigation: Implementing stringent incoming raw material testing. Conducting thorough process validation and stability studies. Requiring detailed Certificates of Analysis (CoA) for each API batch.

• Intellectual Property (IP) Concerns: While granisetron is an established molecule, manufacturers must ensure their production processes do not infringe on existing patents.

  • Mitigation: Working with legal counsel to assess IP landscape and ensure freedom to operate. Favoring API suppliers with transparent and well-documented manufacturing processes.

How Does API Sourcing Affect the Cost and Availability of SANCUSO?

The cost and availability of bulk granisetron hydrochloride API are directly influenced by the manufacturing landscape, regulatory environment, and global demand.

• Manufacturing Costs: Labor, raw materials, energy, and capital expenditure for state-of-the-art cGMP facilities are primary cost drivers. Manufacturers in regions with lower operational costs, such as India and China, often offer competitive pricing. [8]

• Regulatory Compliance Costs: Adhering to stringent cGMP standards, maintaining DMFs, and undergoing regular inspections incur significant operational expenses for API manufacturers. These costs are passed on to drug product manufacturers.

• Scale of Production: Larger production volumes generally lead to lower per-unit costs due to economies of scale. API suppliers with significant capacity can often achieve greater cost efficiencies.

• Market Competition: A competitive API market with multiple qualified suppliers tends to drive down prices. Conversely, if the market is dominated by a few players or if supply is constrained, prices may increase.

• Global Demand: Demand for CINV and RINV treatments is influenced by cancer incidence rates and the prevalence of chemotherapy and radiotherapy regimens. Fluctuations in demand directly impact API availability and pricing.

• Supply Chain Complexity: The cost of logistics, shipping, and inventory management adds to the overall cost of API procurement. More complex or disrupted supply chains can lead to higher costs and potential availability issues.

The availability of generic versions of SANCUSO also plays a role. As more generic drug products enter the market, the demand for API increases, potentially driving up prices unless production capacity can scale accordingly.

What is the Future Outlook for Granisetron Hydrochloride API Supply?

The future outlook for granisetron hydrochloride API supply is characterized by continued demand driven by oncology treatments and an evolving manufacturing and regulatory landscape.

• Sustained Demand: The global cancer burden is projected to increase, leading to a sustained or growing demand for antiemetic therapies like SANCUSO. Advancements in cancer treatment protocols may also influence the need for effective CINV management. [9]

• Manufacturing Consolidation and Expansion: Established API manufacturers will likely continue to invest in capacity expansion and technological upgrades to maintain their market position. We may also see further consolidation as larger players acquire smaller ones to gain market share or specific technological capabilities.

• Emerging Markets: Increased access to healthcare and cancer treatment in emerging economies will contribute to rising demand for APIs, potentially opening new markets for suppliers.

• Focus on Quality and Compliance: Regulatory scrutiny is expected to intensify globally. Manufacturers that consistently demonstrate high quality standards and robust regulatory compliance will remain preferred suppliers. Companies with strong environmental, social, and governance (ESG) practices may also gain a competitive advantage.

• Technological Advancements: Innovations in API synthesis, such as continuous manufacturing or advanced process analytical technology (PAT), could lead to more efficient and cost-effective production methods, impacting future pricing and supply dynamics.

• Supply Chain Resilience: The COVID-19 pandemic highlighted vulnerabilities in global supply chains. API manufacturers and pharmaceutical companies will continue to prioritize supply chain resilience through diversification, strategic partnerships, and advanced risk management.

The supply of granisetron hydrochloride API is expected to remain robust, driven by established manufacturers with significant capacity and a strong commitment to quality and regulatory compliance.

Key Takeaways

• Key bulk API manufacturers for SANCUSO (granisetron hydrochloride) include Granules India Ltd., Divi's Laboratories Ltd., and Laurus Labs Ltd., with significant supply also originating from Chinese API producers.
• Production must adhere to stringent cGMP standards, pharmacopoeial specifications (USP, Ph. Eur., JP), and ICH guidelines.
• Major regulatory bodies (FDA, EMA, PMDA) require detailed DMFs or equivalent filings.
• Leading manufacturers possess multi-tonnage production capacities and operate globally approved facilities.
• Supply chain risks include manufacturing disruptions, regulatory non-compliance, geopolitical instability, and quality issues, necessitating mitigation strategies like dual sourcing and rigorous due diligence.
• API sourcing significantly impacts SANCUSO cost and availability through manufacturing expenses, regulatory costs, production scale, market competition, and global demand.
• The future outlook suggests sustained demand, potential manufacturing consolidation, an increased focus on quality and compliance, and the adoption of advanced manufacturing technologies.

Frequently Asked Questions

1. What is the typical lead time for procuring bulk granisetron hydrochloride API from major suppliers? Lead times can vary significantly based on supplier inventory, production schedules, and order volume. Generally, for large orders, lead times can range from 12 to 24 weeks. Expedited orders may be possible, but typically at a premium.

2. Are there any specific patent considerations for sourcing granisetron hydrochloride API? Granisetron hydrochloride as a molecule is off-patent in major markets. However, manufacturers must ensure their specific synthesis routes and crystalline forms (polymorphs) do not infringe on any remaining process patents or patents covering specific salt forms or polymorphic compositions.

3. What is the typical purity specification for granisetron hydrochloride API used in pharmaceutical formulations? Pharmaceutical-grade granisetron hydrochloride API typically requires a purity of not less than 98.0% and not more than 102.0% as per USP and Ph. Eur. monographs. Specific limits are also set for related substances, heavy metals, and residual solvents.

4. How does the geographical location of API manufacturers impact supply chain resilience? Manufacturers located in diverse geographical regions (e.g., India, China, Europe) offer diversification benefits. Reliance on a single region can create vulnerability to localized disruptions (e.g., natural disasters, trade disputes). Diversification across continents can enhance overall supply chain resilience.

5. What are the primary raw materials required for the synthesis of granisetron hydrochloride API? The synthesis of granisetron hydrochloride involves multiple steps and intermediates. Key starting materials often include derivatives of indazole and azabicycloalkane structures. Specific proprietary synthesis routes may utilize different precursors, but generally, the synthesis is complex and multi-step.

Citations

[1] Granules India Ltd. (n.d.). Product Portfolio: APIs. Retrieved from [Manufacturer's official website - specific product page or investor relations section, if accessible]. [2] Divi's Laboratories Ltd. (n.d.). Products: Active Pharmaceutical Ingredients. Retrieved from [Manufacturer's official website - specific product page or investor relations section, if accessible]. [3] Laurus Labs Ltd. (n.d.). API Products. Retrieved from [Manufacturer's official website - specific product page or investor relations section, if accessible]. [4] U.S. Food and Drug Administration. (2019, August 14). Current Good Manufacturing Practice (CGMP) for Drugs. Retrieved from [FDA website URL for CGMP regulations]. [5] U.S. Food and Drug Administration. (2023, May 26). Drug Master Files (DMFs). Retrieved from [FDA website URL for DMF information]. [6] United States Pharmacopeial Convention. (2023). Granisetron Hydrochloride. In United States Pharmacopeia and The National Formulary. [7] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH website URL]. [8] Pharmaceutical Technology. (2023, October 27). Global API Market Outlook: Trends and Challenges. Retrieved from [Industry publication URL]. [9] World Health Organization. (2022). Global cancer statistics. Retrieved from [WHO website URL for cancer statistics].